Sign in

CIK 0001652130 · Large accelerated filer

Intellia Therapeutics, Inc.

Sign in to watch
Ticker
NTLA
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
364785571
Phone
857-285-6200
Business address
400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
  1. 4 Open-market sale EVP, Chief Scientific Officer sold 26,000 shares at an average $138.24 ($3,594,357)
  2. 4 Open-market sale EVP, Chief Financial Officer sold 20,000 shares at an average $151.05 ($3,021,056)
  3. 10-Q Report Quarterly Report
  4. 8-K Event Results of operations
  5. 4 Derivatives Options or other derivatives
  6. 3 Insider Initial Statement of Ownership
  7. 8-K Event Material agreement
  8. 424B5 Offering Prospectus
  9. 4 Open-market sale Director sold 553,376 shares at an average $132.73 ($73,448,879)
  10. 424B5 Offering Prospectus
  11. 8-K Event Regulation FD disclosure · Other events
  12. 4 Grant or award Director acquired 2,094 shares (grant or award)
  13. 4 Grant or award Director acquired 2,094 shares (grant or award)
  14. 4 Grant or award Director acquired 2,094 shares (grant or award)
  15. 4 Grant or award Director acquired 2,094 shares (grant or award)
  16. 4 Grant or award Director acquired 2,094 shares (grant or award)
  17. 4 Grant or award Director acquired 2,094 shares (grant or award)
  18. 4 Grant or award Director acquired 2,094 shares (grant or award)
  19. 8-K Event Shareholder vote results
  20. 8-K Event Executive or director change · Other events

Page 18 of 37 · 725 filings